USA 117 , 2866728677 (2020)
this off-label use is not backed by the same level of controlled human trial evidence as the lipodystrophy indication Known risks and side effects: Injection site reactions, including erythema, pruritus, pain, and bruising at the injection site Arthralgia (joint pain) and peripheral edema (fluid retention), recognized class effects of GH-axis stimulation Increases in blood glucose and reduced insulin sensitivity, with clinical trials showing a higher rate of elevated HbA1c and new-onset hyperglycemia versus placebo Formation of anti-tesamorelin antibodies, reported in a substantial proportion of treated patients, with unclear long-term clinical significance Contraindicated in people with active malignancy, pituitary or hypothalamic disruption, or pregnancy, per FDA labeling Evidence snapshot: The strongest evidence is a set of Phase 3 human randomized controlled trials that supported FDA approval of tesamorelin for reducing visceral abdominal fat in HIV-associated lipodystrophy (approved 2010), plus a separate placebo-controlled human RCT (Baker et al., 2012, Archives of Neurology) showing improved executive function in older adults
Key considerations include: Variability in clinical efficacy based on formulation Trade-offs between adherence and dosing efficiency Emerging safety and regulatory developments As delivery technologies improve, oral peptides may expand access and improve patient experiencebut their long-term role will depend on consistent clinical outcomes and quality assurance
Dosing Protocol A suggested titration approach based on common reference doses for GHK-Cu
Thermage uses focuses radiofrequency to heat specific areas within the skin
not for human or veterinary application References Larsen P.J
